NHN Becomes a Hub of Medical Excellence

Industry: Healthcare & Pharma, Hospital, Clinic & Diagnostic, NGO, NGO & Development
Company: National Healthcare Network (NHN)
Company Intelligence Tag: Business Insights

The National Healthcare Network (NHN), an initiative by the Diabetic Association of Bangladesh (BADAS), has emerged as a cost-effective hub of medical excellence, featuring seven hospitals and 23 medical centers. NHN’s primary aim is to provide quality diagnostic services nationwide at affordable rates. With costly medical equipment at the core of their operations, NHN seeks profitability to ensure sustained equipment acquisition. The 3rd NHN Scientific Meeting discussed digitization’s role in healthcare and NHN’s plans to expand across the country while maintaining affordability and service quality. NHN’s ambitious expansion plans align with its vision to become a healthcare leader by collaborating with other institutions to broaden its health programs.

Source for more details:

Related News

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

DWASA Project Cost Rises 126% to Tk 109.75b with 11-Year Delay

April 13, 2025

The cost of DWASA’s 'Dhaka Environmentally Sustainable Water Supply Project' has surged by Tk 28.28 billion in its third revision, raising the total estimated budget to Tk 109.75 billion—126.38% higher than the original Tk 48.48 billion approved in 2013. Despite an 11-year delay and 87% physical progress, the project remains incomplete.

Related News

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

DWASA Project Cost Rises 126% to Tk 109.75b with 11-Year Delay

April 13, 2025

The cost of DWASA’s 'Dhaka Environmentally Sustainable Water Supply Project' has surged by Tk 28.28 billion in its third revision, raising the total estimated budget to Tk 109.75 billion—126.38% higher than the original Tk 48.48 billion approved in 2013. Despite an 11-year delay and 87% physical progress, the project remains incomplete.

BUSINESSMONITOR

Connect with


Dont Have Account? Please register Here